Four of Katten's Intellectual Property attorneys co-authored a chapter of "Biosimilars Litigation and Client Counseling," published by The American Bar Association (ABA), under the section titled "Advising Clients on Product Strategies, Global Considerations, and the Future of BPCIA and Biosimilars." New York Partners Deepro Mukerjee, Intellectual Property department chair, and Lance Soderstrom, Patent Litigation co-chair, along with Chicago Counsel Matthew Holub and Dallas Associate Jillian Schurr, wrote a chapter about product case studies that delves into matters related to Abbvie's Humira® (adalimumab), Amgen's Neupogen® (filgrastim)/Neulasta® (pegfilgrastim) and Genentech's Herceptin® (transtuzumab). Deepro and Lance also contributed as associate editors on the book's Board of Editors.
The ABA describes "Biosimilars Litigation and Client Counseling" as a thorough guide "to the field of biologic products and biosimilars, as well as the laws governing them," including the Biologics Price Competition and Innovation Act. The book intends to provide attorneys, judges, and pharmaceutical managers or decision-makers with a comprehensive reference and useful analysis of legal processes and challenges in this area, summarizing both the statutory and regulatory framework for applying for and receiving a biologic and biosimilar application.
"Biosimilars Litigation and Client Counseling," The American Bar Association, June 17, 2024
